Clinical trial strategy was developed through research on a gene associated with treatment-resistant prostate cancer
Durvalumab monotherapy appears safe and well-tolerated
Clinical efficacy uncompromised in previously untreated patients
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy